CN
2024-08-27 05:42
AsymBio Congratulates Multitude Therapeutics on IND Approval of AMT-676 by NMPA
返回

Multitude 英文.jpg


Multitude Therapeutics, a strategic partner of AsymBio, announced National Medical Products Administration (NMPA) has accepted the company’s IND application for AMT-676, an anti-CDH17 antibody-drug conjugate (ADC). AsymBio, the leading CDMO solutions provider, warmly extends congratulations on this major milestone achievement.

With this IND approval, Multitude Therapeutics will be able to conduct phase 1 clinical trials in China for patients with advanced solid tumors, which will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMT-676.

We look forward to continuing our collaboration to advance their clinical trials to solve unmet medical needs for patients worldwide.